PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
94.81%
Net income growth above 20% – Outstanding. Warren Buffett would verify whether this rise is driven by core operations or one-time items.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-170.14%
A negative yoy change in working capital can free up cash. Benjamin Graham would confirm it is not from falling demand or asset disposal.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
A negative yoy AP change means the firm is paying down supplier credit. Benjamin Graham would see it as lowering short-term liabilities if revenue is stable.
-452.30%
A negative yoy shift in other WC might free up cash flow. Benjamin Graham would confirm the items are not essential to operations or revenue generation.
No Data
No Data available this quarter, please select a different quarter.
12.59%
Operating cash flow growth 10-15% – Solid. Seth Klarman would see a healthy sign for near-term liquidity and reinvestment.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Issuance above 15% yoy – Significant equity raise. Philip Fisher would require a very compelling reason to risk heavy shareholder dilution.
No Data
No Data available this quarter, please select a different quarter.